OncoMyx Therapeutics

OncoMyx Therapeutics, founded in 2018 and headquartered in Phoenix, Arizona, is dedicated to developing innovative cancer treatments. The company's core mission is to harness the power of oncolytic immunotherapies to create effective cancer treatments. Their primary product is a myxoma virus (MYXV) platform designed to target both hematologic and solid tumors. This platform employs a patented systemic delivery method that uses human leukocytes to transport the virus, enabling it to infect and destroy tumor cells. OncoMyx aims to revolutionize cancer treatment by leveraging this unique approach.

The company has garnered attention through its pioneering work and has attracted notable investors and affiliations within the biotech industry. Key achievements include the successful development and initial testing of their MYXV platform, demonstrating its potential efficacy in preclinical models. OncoMyx Therapeutics' innovative approach has positioned it as a promising player in the field of cancer treatment, with the potential to significantly impact patient outcomes and advance the standard of care in oncology.